Since the launch of The Genetic Link blog back in 2009, we’ve shared dozens of stories from the field highlighting remote DNA collections, innovative approaches to research, and unique event-based collections. Each of these stories was based on a research team searching for the gene or genes responsible for a particular disease or health condition. The story in this article is unique in that it highlights a project that is hoping to attract individuals who are willing to share their personal genome, health information and trait data for a broader application. The goal is to advance scientific progress by inviting willing participants to share their personal genetic data for the greater good.
DNA Genotek's Sample Collection Blog
DNA Genotek is a recognized leader in the biostabilization technology field and today, we received a new honor for our work in this area. Our HEMAgene™•BUFFY COAT stabilizing reagent received the 2014 Outstanding Product Award from the International Society for Biological and Environmental Repositories (ISBER) at their annual meeting in Orlando, Florida, USA. The ISBER Annual Meeting is widely recognized as the premier event in the field of repository and specimen management.
In a recent article on The Genetic Link, we talked about our quality and regulatory process and the benefits this brings to our customers. Today, I am focusing on the work we do behind the scenes to make sure our products can be used by researchers around the world.
The author of this article, Lisa Gamwell, is a Sales Development Analyst at DNA Genotek.
Post-traumatic stress disorder (PTSD) is a type of anxiety disorder that can occur after an individual has experienced an extreme emotional trauma involving the threat of injury or death. It is not known why traumatic events cause PTSD in some people but not in others, however, factors such as genes, emotions, and family setting may all play roles.
Over the past few months, we’ve been posting a series of blog articles on the topic of genetics and mental health. This month, we have an exciting story to share with you on the growing role of genetics in understanding a range of psychiatric disorders from an institution that is breaking new ground in this important research area.
We always enjoy hearing about how our customers are using our products for innovative projects. Recently, we learned about a new project in Germany called GeneTalk, which uses Oragene to collect DNA from saliva. GeneTalk is what many physicians and scientists working on human next generation sequencing (NGS) data sets have been waiting for. We know that NGS is an effective method for identifying rare disease causing variants associated with genetic disorders and as a valuable tool for diagnosing and treating many other diseases. The challenge in analyzing the sequence variants of a patient is to discriminate between all the variants without medical relevance and the mutations that actually have an impact on the disease. Many believe that a large database of exomes from healthy controls may help to create this benchmark and thus speed up the identification of the mutations causing genetic disorders. This is where GeneTalk comes in.
DNA Genotek is proud to provide a high level of service and support to our customers. We know that our success as a company is tightly integrated with the success of our customers and we are committed to providing access to a team of skilled scientists and creative resources to optimize genetic projects from sample collection through to downstream processing.
At the 2013 American Society for Human Genetics (ASHG) conference in Boston last month, we launched the first version of DNA Genotek’s Activity Calendar for science fanatics. We wanted to provide ASHG attendees who visited our booth a way to celebrate scientific achievement in a fun way. The end result is a glossy, full color, 13-month desk calendar that features a variety of puzzles, challenges and games. Each month includes an online challenge which must be completed to be entered into a draw for a 32GB Apple iPad Mini (Wi-Fi version).
Dr. Janet Coller, Lecturer at the University of Adelaide, has an established track record in Pharmacology and Pharmacogenetic medical research within the health areas of cancer, drug dependence, cardiology and solid-organ transplantation. Her research includes work to identify how genetic variability impacts the therapeutic use of tamoxifen for breast cancer, identifying important genetic variants that determine successful treatment of opioid dependence with methadone, and research in the emerging field of immunogenetics.